Cell>Point Announces Encouraging Results From 99mTc-EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease  
4/10/2013 12:09:29 PM

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled EthylenediCysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of ischemia in patients with Coronary Artery Disease (CAD).